Robust antibody response after 3 doses of mRNA COVID-19 vaccine in hemodialysis patients
Not Applicable
Completed
- Conditions
- hemodialysis patients
- Registration Number
- JPRN-UMIN000047083
- Lead Sponsor
- Fujita Memorial Hospital
- Brief Summary
Significant SARS-CoV-2 antibody production is observed in hemodialysis patients after three doses of mRNA COVID-19 vaccine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 283
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with no history of COVID-19
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Degree of increase in SARS-CoV-2 antibody titer after mRNA COVID-19 vaccination
- Secondary Outcome Measures
Name Time Method